Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib + GnP in Pancreatic Adenocarcinoma
NCT06398587Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in pancreatic ductal adenocarcinoma (PDAC), sponsored by OHSU Knight Cancer Institute. Planned start Aug 2024; status: withdrawn.
02
Drugs
onvansertib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06398587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398587.